GLUE — Monte Rosa Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1826457 ·
Last close
$9.07
Market Cap
$775.03M
52W High
$25.77
52W Low
$8.83
ADV30
1,459,282
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 54,366,000 | — | -1,939,000 | 3,063,000 | 697,725,000 | 45,180,000 | 201,517,000 |
| Jun 2026 | 8,968,000 | — | -49,130,000 | -43,397,000 | 691,161,000 | 90,104,000 | 203,880,000 |
| Mar 2026 | 4,210,000 | — | -50,034,000 | -44,503,000 | 736,428,000 | 159,859,000 | 214,512,000 |
| Dec 2025 | 2,781,000 | — | -49,715,000 | -46,135,000 | 448,659,000 | 129,883,000 | 215,603,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-165,475,000
Investing CF
$-359,458,000
Financing CF
$361,738,000
CapEx
$-8,916,000
Dividends Paid
—
Buybacks
$-357,000
EPS Diluted TTM
$-1.70
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-562,051,000
Inventory
—
Receivables
$57,624,000
ST Investments
$532,546,000
EBIT TTM
$-150,818,000
Pretax Income TTM
$-129,937,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$28,727,000
EBITDA
$-173,728,000
Free Cash Flow
$-74,449,752
Enterprise Value
$339,973,984
Total Cash
$621,104,000
Total Debt
$37,987,000
Shares Out
85,450,119
Trailing EPS
$-1.39
Book Value
$3.56
ROE
-42.7%
ROA
-21.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 123,672,000 | -54,208,000 | -38,626,000 | 448,659,000 | 215,603,000 | 233,056,000 | -22,798,000 |
| Dec 2024 | 75,622,000 | -81,112,000 | -72,700,000 | 438,732,000 | 215,796,000 | 222,936,000 | 41,996,000 |
| Dec 2023 | 0 | -143,311,000 | -135,352,000 | 303,755,000 | 124,505,000 | 179,250,000 | -43,802,000 |
| Dec 2022 | 0 | -112,384,000 | -108,501,000 | 342,389,000 | 70,976,000 | 271,413,000 | -92,466,000 |
TTM Snapshot
Revenues TTM
$28,727,000
NetIncome TTM
$-161,116,000
OpCashFlow TTM
—
Assets (Latest)
$691,161,000
Forward EPS
$-1.81
Max Pain — expiry 2027-04-16
max pain strike: $12.50 · spot: $9.07 · call oi: 2,079 · put oi: 1,810
Expected Move to 2027-04-16:
±$5.38
(59.26%) —
implied range
$3.69 –
$14.44
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AURA | Aura Biosciences, Inc. | $744.13M | $7.15 | — |
| MGTX | MeiraGTx Holdings plc | $826.80M | $8.46 | — |
| BBTX | Bambusa Therapeutics, Inc. | $832.91M | $16.35 | — |
| PRME | Prime Medicine, Inc. | $854.20M | $3.84 | — |
| SLDB | Solid Biosciences Inc. | $695.33M | $6.23 | — |
News headlines (Yahoo Finance, 1h cache)
Monte Rosa Therapeutics (GLUE) Stock Fair Value Edges Lower As Analysts Weigh NEK7 Promise And Risk
2026-11-11 04:32 · Yahoo
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
2026-11-09 12:00 · Yahoo
Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates
2026-11-05 13:35 · Yahoo
Monte Rosa Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:58 · Yahoo
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
2026-11-05 12:00 · Yahoo
Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
2026-11-03 13:55 · Yahoo
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
2026-11-02 12:00 · Yahoo
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2026-10-29 13:00 · Yahoo
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
2026-10-28 11:00 · Yahoo
Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?
2026-10-23 10:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.